Introduction
============

Gastric cancer is one of the most common human digestive tract malignancies, affected by various factors, including dietary habits, environmental factors and the prevalence of *Helicobacter pylori* infection ([@b1-ol-0-0-9705]). A total of 951,600 new gastric cancer cases and 723,100 mortalities are estimated to have occurred in 2012, making it the third leading cause of cancer-associated mortality globally ([@b1-ol-0-0-9705]). Almost 66% of gastric cancer cases and mortalities occur in less-developed regions, particularly in Eastern Asia ([@b1-ol-0-0-9705]). China is one of the countries with a high incidence of gastric cancer, and accounts for \>40% of all new gastric cancer cases worldwide ([@b1-ol-0-0-9705],[@b2-ol-0-0-9705]). Previous studies indicate a declining trend in gastric cancer-associated mortalities has been reported due to improvements in quality-of-life and treatment techniques ([@b3-ol-0-0-9705],[@b4-ol-0-0-9705]). At present, pre-operative chemotherapy is widely used as a preliminary treatment for locally-advanced gastric cancer to aid total resection and improve survival ([@b5-ol-0-0-9705]). It is assumed that neoadjuvant chemotherapy has a relatively short-term benefit, based on the tumor regression grade ([@b6-ol-0-0-9705]). Several studies have reported a close association of the tumor regression grade with clinic opathological characteristics and patient survival ([@b6-ol-0-0-9705]--[@b9-ol-0-0-9705]). However, the tumor response to preoperative chemotherapy is not uniform among patients, and there are currently no effective methods to predict the outcome of treatment. Molecular markers have been suggested to have potential for early detection of disease, and for predicting response to therapy ([@b10-ol-0-0-9705],[@b11-ol-0-0-9705]). Therefore, identifying specific and sensitive novel markers that may predict the efficacy of neoadjuvant chemotherapy may be useful for making decisions in the management of patients with gastric cancer.

Aldo-ketoreductase family 1 member B10 (AKR1B10) is a member of the aldo-ketoreductasesuperfamily, a cytosolic nicotinamide adenine dinucleotide phosphate-dependent oxidoreductase enzyme that metabolizes carbohydrates, steroids, prostaglandins and exogenous carbonyl compounds ([@b12-ol-0-0-9705]). Although the functions of AKR1B10 intumorigenes is remain unclear, it is hypothesized that AKR1B10 may serve functions in cancer development and progression via multiple molecular mechanisms including the detoxification of cytotoxic carbonyls, modulation of retinoic acid levels, and regulation of cellular fatty acid synthesis and lipid metabolism ([@b13-ol-0-0-9705]--[@b15-ol-0-0-9705]). AKR1B10 is predominantly expressed in the gastrointestinal tract, particularly in the small intestine and colon, and in other organs, including the liver, pancreas, thymus and adrenal gland ([@b16-ol-0-0-9705]). However, overexpression of AKR1B10 has been reported in numerous solid tumors, including hepatocellular carcinoma, non-small cell lung cancer, breast cancer and pancreatic cancer ([@b17-ol-0-0-9705]--[@b20-ol-0-0-9705]), while reduced expression has been reported in colon, stomach, and head and neck cancer ([@b21-ol-0-0-9705]). Only a small number of studies have explored the association between AKR1B10 expression and clinic opathological parameters of gastric cancer. To our knowledge, the present study is the first to have investigated the immunohistochemical expression of AKR1B10 and identified the clinic opathological parameters that predicted the response of gastric tumors to neoadjuvant chemotherapy in 53 patients with gastric carcinoma.

Materials and methods
=====================

### Reagents and cell lines

Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Immobilon-P (cat. no. IPVH00010) was purchased from Merck Millipore (Merck KGaA, Darmstadt, Germany). ECL kit (cat. no. WBKLS0500) was from Millipore (Billerica, MA, USA). An antibody against rabbit AKR1B10 used in the present study was synthesized and used as previously described ([@b22-ol-0-0-9705],[@b23-ol-0-0-9705]). The Lamin B1 antibodies (cat. no. sc-20682) was supplied by Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). α-tubulin (cat. no. T6199) was purchased from Merck KGaA (Darmstadt, Germany). Horseradish peroxidase (HRP) conjugated goat anti-rabbit antibody (cat. no. HA1001) was obtained from Hua-an Biotechnology (Hangzhou, Zhejiang, China). The human gastric cancer cell lines AGS and BGC-823 were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI-1640 growth medium supplemented with 10% fetal bovine serum and penicillin-streptomycin. All cell lines were cultured as described previously ([@b24-ol-0-0-9705]).

### Western blot analysis for detection of AKR1B10 expression in gastric cancer cell lines

AGS and BGC-823 cells were grown in Dulbecco\'s modified Eagles\' medium supplemented with 10% fetal calf serum and 100 units/ml penicillin and streptomycin (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). Cells were washed three times with Hepes-buffered, modified Krebs-Henseleit buffer (118 mMNaCl, 4.69 mMKCl, 1.18 mMMgSO~4~, 1.29 mMCaCl~2~, 1.18 mMKH~2~PO~4~, 11.67 mMglucose, 25 mMHepes, pH 7.4 at 37°C) and gently re-suspended cells in 500 µl Hypotonic Buffer (20 mMTris-HCl, pH 7.4, 10 mMNaCl, 3 mM MgCl~2~) by pipetting up and down several times. Following a 15 min incubation on ice, 25 µl detergent was added (10% NP40) and vortexed for 10 sec at the highest setting. The homogenate were centrifuged for 10 min at 1,000 × g at 4°C. The nuclear pellet was resuspended in 50 µl complete Cell Extraction Buffer (10 mMTris, pH 7.4, 2 mM Na~3~VO~4~, 100 mMNaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM EGTA, 0.1% SDS, 1 mMNaF, 0.5% deoxycholate, 20 mM Na4P~2~O~7~, 1 mM PMSF) for 30 min on ice with vortexing at 10 min intervals. The extract was centrifuged for 30 min at 14,000 × g at 4°C. Quantification of protein concentration was performed using Bradford assay. Protein samples (100 µg) were separated by 10% SDS-PAGE as described previously ([@b24-ol-0-0-9705],[@b25-ol-0-0-9705]). The membrane carrying the transferred proteins were blocked with 5% non-fat milk powder in PBS, 0.3% Tween 20 for 2 h at room temperature. The membranes were incubated with AKR1B10 primary antibody (dilution, 1:5,000) for 1 h at room temperature, washed with blocking buffer 3--4 times (5 min per wash at room temperature), the membranes were then incubated with the HRP-conjugated goat anti-rabbit antibody (dilution, 1:5,000) secondary antibody. Protein bands were detected by developing blot using the ECL kit (Merck Millipore) according to the manufacture\'s protocol. Subsequently to confirm nuclear and cytoplasmic fractions immunoblotting was carried out with nuclear marker anti-Lamin B1 antibodies (dilution, 1:500) and anti-tubulin antibodies (dilution, 1:2,000). The relative levels of the protein of interest were calculated by quantification of band intensity with an Odyssey infrared imaging system from LI-COR^®^ Biosciences (Lincoln, Nebraska, USA).

### Patients and samples

The present study recruited 53 patients with gastric carcinoma who received different chemotherapy regimens, including epirubicin + cisplatin + capecitabine (ECX), epirubicin + oxaplatin + tegafur (EOS), epirubicin + oxaplatin + capecitabine (EOX), oxaplatin + leucovorin +5-FU (FOLFOX), and (S1) tegafur and oxaplatin + tegafur (SOX) prior to surgery between January 2006 and December 2015 at the Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Zhejiang, China). All specimens were biopsy materials taken subsequent to preoperative chemotherapy. The patient\'s response to chemotherapy was evaluated following two courses of chemotherapy according to response evaluation criteria in solid tumors (RECIST) criteria ([@b26-ol-0-0-9705]). Surgery was performed within 1--2 weeks of completion of neoadjuvant chemotherapy. Depending on the location and macroscopic type of gastric cancer, patients underwent total, distal, or proximal subtotal gastrectomy. The patients age ranged between 33 and 77 years (median 58 years; mean 58.15). The study population comprised 40 males and 13 females. Clinic opathological factors recorded were age, sex, tumor size, tumor location, tumor staging, tumor depth, lymph node metastasis, histological differentiation and response to neoadjuvant chemotherapy. A receiver operating characteristics curve ([Table I](#tI-ol-0-0-9705){ref-type="table"}) was used to define the cut-off point for various variables relative to AKR1B10 expression. The staging of gastric cancer was according to the rules of the 6th edition of American Joint Commission on Cancer system (AJCC) manual ([@b27-ol-0-0-9705]). Patients were recommended for neoadjuvant chemotherapy based on the criteria of histologically-proven gastric cancer, Eastern Cooperative Oncology Group performance status ([@b28-ol-0-0-9705]), clinical stage ≥T2 or lymph node metastasis, satisfactory organ function, and no active associated malignancy. Patients were monitored by upper gastrointestinal endoscopy and/or ultrasound endoscopy and abdominal computed tomography scanning. For tumor differentiation, well- and moderately differentiated adenocarcinoma, papillary adenocarcinoma, and well-differentiated mucinous adenocarcinoma were considered to be differentiated, whereas poorly-differentiated adenocarcinoma, signet ring cell carcinoma, and poorly-differentiated mucinous adenocarcinoma were designated undifferentiated. Surgeons, oncologists and radiologists individually evaluated all cases at the Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. The discrepancies were resolved by consensus review. The present study protocol was based on the Sir Run Run Shaw Hospital\'s policies and comprised chemotherapy and radio-chemotherapy, dependent upon tumor location. Multiple chemotherapeutic regimens were used, as aforementioned, and the tumor response to neoadjuvant treatment was reviewed using the tumor regression grade (TRG) scale introduced by Mandard *et al* ([@b29-ol-0-0-9705]). Tumor regression was graded as TRG 4, complete regression; TRG 3, isolated cell nests; TRG 2, increased number of residual cancer cells with predominant fibrosis; TRG 1, residual cancer outgrowing fibrosis; and TRG 0, no regressive changes. The patients were followed up until the last follow-up date or until they succumbed to mortality. The median follow-up period was 19 months (range, 1--67 months). Of the 53 patients, 17 (32.1%) succumbed during the follow-up period. The Human Ethics Review Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine approved the present study and informed written consent was obtained from patients regarding the use of biopsy materials for the present study.

### Immunohistochemistry (IHC)

AKR1B10 expression in paraffin-embedded tumor samples (4-µm thick sections) were evaluated by IHC staining using standard procedures ([@b24-ol-0-0-9705],[@b25-ol-0-0-9705]). In brief, tissue slides were deparaffinized in xylene and then rehydrated through graded ethanols. The slides were incubated with the AKR1B10 antibody (1:3,000) overnight at 4°C. The reacted antibody was visualized with the Vector Laboratories ImmPRESS Detection kit, according to the manufacturers protocols, included a horseradish peroxidase-conjugated secondary antibody and a diaminobenzidine-based stain. Finally, sections were counterstained with Mayer\'s hematoxylin, dehydrated and mounted ([@b23-ol-0-0-9705]).

### Immunohistochemical evaluation and scoring

Protein expression was quantified by two independent pathologists of Sir Run Run Shaw Hospital (Zhejiang University School of Medicine) who were blinded to the clinical data. Representative images were captured under a light microscope (Olympus BX61, Shanghai, China; magnification, ×600). AKR1B10 expression was detected in the cytoplasm of tumor cells in gastric carcinoma and assessed based on the staining intensity and proportion of positive cells. The staining intensity was scored from 0 to 3+ as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+, strong staining. AKR1B10-positive cells were expressed as a percentage and divided into four grades: Grade 0, \<5% positive; grade 1, 5--25% positive; grade 2, 26--50% positive; and grade 3, \>50% positive cells. The total score was obtained by multiplying these two results (range 0--9) and samples were divided into two groups: Negative expression (≤4) and positive expression (\>4). The threshold value of 4 was selected since the median score ([@b30-ol-0-0-9705]) of AKR1B10 expression in gastric cancer samples was 4.5 in the present study.

### Statistical analysis

Statistical analysis was carried out using SSPS software for Windows (version 16.0; SPSS, Inc., Chicago, IL, USA). The significant associations between AKR1B10 expression and various clinic opathological parameters were determined by the χ^2^ or Fisher\'s exact tests. The Kaplan-Meier test was used to evaluate patient survival and the log-rank test for data analysis. Prognostic factors were assessed by univariate and multivariate analyses (Cox proportional hazards regression model). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Among the 53 patients, 40 were men and 13 women

Their age ranged from 33 to 77 years (median, 58 years). The tumor size in the majority of patients was \<5 cm (64.2%). In addition, lymph node metastasis was present in 68% of patients and the depth of tumor invasion was T3 or T4 in 79.2%. Following neoadjuvant chemotherapy 20 patients (37.7%) exhibited tumor regression (TRG 3 or 4) as defined here, and complete regression occurred in 5 patients. The patient data is summarized in [Table I](#tI-ol-0-0-9705){ref-type="table"}.

### Expression of AKR1B10 in gastric cancer cell lines

Western blotting was carried out to detect the AKR1B10 expression in nuclear and cytoplasmic fractions of gastric cancer cell lines. The results identified that AKR1B10 can be readily detected, and was predominantly expressed in cytoplasm in both AGS and BGC-823 cells. Notably, the expression of AKR1B10 is approximately 5-fold higher in BGC-823 cells than that in AGS cells ([Fig. 1](#f1-ol-0-0-9705){ref-type="fig"}).

### Expression of AKR1B10 in gastric cancer and its association with clinic opathological features

The expression and subcellular localization of AKR1B10 were determined in paraffin-embedded biopsy specimens of gastric cancer. Immunohistochemistry revealed that AKR1B10 protein was primarily expressed in the cytoplasm of gastric cancer cells ([Fig. 2](#f2-ol-0-0-9705){ref-type="fig"}), and demonstrated that the antibody used had a strong potency as well as consistency with a previous study ([@b31-ol-0-0-9705]). AKR1B10 immunoreactivity was detected in 31 gastric carcinoma samples. The positive rate of AKR1B10 protein expression was 58.5% with an overall score \>4, whereas 22 (41.5%) samples exhibited negative expression with a score ≤4. To evaluate the role of AKR1B10 in gastric cancer the correlation between AKR1B10 expression and the patients\' clinic opathological features was assessed ([Table II](#tII-ol-0-0-9705){ref-type="table"}). No correlation was been observed between the expression level of AKR1B10 protein and patient age, sex, tumor size, tumor location, tumor staging, tumor depth or and histological differentiation. However, the frequency of AKR1B10-positive reactivity was higher in gastric cancer with lymph node metastasis than in that without metastasis (69.4%, 25/36 vs. 35.3%, 6/17; P=0.020). The proportion of AKR1B10-positive samples was higher in patients with decreased tumor regression following neoadjuvant chemotherapy than in those with tumor regression grades 3 and 4 (69.7%, 23/33 vs. 40%, 8/20; P=0.033).

### Survival analysis

Overall survival of between 1 and 67 months occurred in the 53 gastric cancer cases, and the median overall survival was 19 months. Follow up results indicated that the mean survival time of patients with gastric cancer with neoadjuvant chemotherapy with AKR1B10-negative samples was 25.0 months, while in those with AKR1B10-positive samples the mean overall survival was 19.5 months. Patients were classified as alive (67.9%; n=36/53) or dead (32.1%; n=17/53) according to the final follow-up on Dec 31, 2015. Kaplan-Meier survival analysis indicated that patients with positive AKR1B10 expression had poorer survival rates than those with negative AKR1B10 expression (P=0.0372; [Fig. 3](#f3-ol-0-0-9705){ref-type="fig"}). Univariate analysis for age, sex, tumor size, tumor location, tumor stage, tumor depth, lymph node metastasis, histological type, and tumor response to neoadjuvant chemotherapy revealed significant associations of tumor location (P=0.0237), tumor stage (P=0.0066), lymph node metastasis (P=0.0006) and tumor regression (P=0.0496) with overall survival, while the other factors exhibited no such association ([Table III](#tIII-ol-0-0-9705){ref-type="table"}).

Furthermore, multivariate analysis was performed on the factors. Analysis identified lymph node metastasis, tumor regression grade and AKR1B10 expression as independent prognostic predictors for overall survival, presented in [Table III](#tIII-ol-0-0-9705){ref-type="table"}.

Discussion
==========

Gastric cancer is a heterogeneous disease with distinct biological behaviors. Previously, neoadjuvant chemotherapy has been considered the primary choice of treatment in locally advanced gastric cancer due to the survival advantage of combined chemotherapy and surgery over surgery alone ([@b5-ol-0-0-9705],[@b32-ol-0-0-9705]). Multiple studies have demonstrated the efficacy of chemotherapeutic agents by assessing the clinical and pathological responses of tumors ([@b6-ol-0-0-9705]). A World Health Organisation-based evaluation of the clinical response in gastric cancer using conventional staging modalities, including endoscopic ultrasonography and CT contrast, was inaccurate ([@b33-ol-0-0-9705],[@b34-ol-0-0-9705]), while assessment of post-chemotherapy histological change, another technique for assessing the tumor response, was considered highly useful ([@b35-ol-0-0-9705]). Mandard\'s tumor regression grade ([@b29-ol-0-0-9705]) predicts the pathological response to cytotoxic agents. The clinical usefulness of these studies remains unclear, therefore, it is important to identify precise molecular markers which predict the effectiveness of neoadjuvant chemotherapy for improved management of patients with gastric cancer. In the present study, it was identified that AKR1B10 protein expression in gastric cancer was significantly associated with patient survival. In this context, to the best of our knowledge, this is the first study to demonstrate the role of AKR1B10 in gastric cancer with neoadjuvant chemotherapy.

Multiple studies have identified that AKR1B10 is highly expressed in many solid tumors outside the digestive tract, including non-small cell lung cancer, breast cancer, pancreatic cancer and hepatic cancer ([@b17-ol-0-0-9705]--[@b20-ol-0-0-9705]). Clinicopathological studies in liver tumors have reported that AKR1B10 may be a useful biomarker of tumor proliferation and differentiation as well as being responsible for the initial phases of hepatocarcinogenesis ([@b17-ol-0-0-9705],[@b35-ol-0-0-9705]). Notably, downregulated AKR1B10 expression has been reported in gastrointestinal cancers without pre-operative treatment and its expression correlates with increased overall survival ([@b30-ol-0-0-9705],[@b36-ol-0-0-9705]). In the present study, the expression of AKR1B10 protein was investigated using immunohistochemical staining in 53 gastric cancer biopsies taken from patients who received preoperative chemotherapy. Immunoreactivity was predominantly detected in the cytoplasm. This result was consistent with the expression of AKR1B10 in primary resected gastric tumor reported by Yao *et al* ([@b31-ol-0-0-9705]). Among the 53 samples, AKR1B10 positive expression was observed in 31/53 gastric carcinoma samples and tended to be increased in patients with lymph node metastasis compared with patients without metastasis. Furthermore, the rate of AKR1B10-positivity was significantly increased in samples from patients with less tumor regression compared with patients exhibiting complete or nearly-complete regression. Although AKR1B10-negative protein expression was observed in tumor regression grades 3 and 4, the associations between AKR1B10 expression and other clinical factors were not significant. Furthermore, Kaplan-Meier survival curves were used to investigate the association between AKR1B10 expression and survival. The results revealed that patients with AKR1B10-positive samples experienced significantly poorer survival than those with AKR1B10-negative samples. A previous study by Yao *et al* ([@b36-ol-0-0-9705]) reported that positive AKR1B10 staining was also markedly associated with lymph node and distant metastasis, tumor size, and Tumor-Node-Metastasis stage. The present results differ from previous studies, possibly due to the fact that the samples were biopsy materials taken following preoperative chemotherapy. Concurrently, survival time and other clinic opathological factors were investigated by univariate analysis to identify any associations. Notably, it was identified that tumor stage, tumor location, lymph node metastasis and tumor regression were significantly associated with survival. Wang *et al* ([@b6-ol-0-0-9705]) reported similar results regarding tumor regression. Additionally, lymph node metastasis, tumor regression grade and AKR1B10 expression were selected as independent prognostic predictors via multivariate analysis. Based on the above findings, it may be concluded that AKR1B10 expression is associated with lymph node metastasis and a worse prognosis in patients with a poor response to neoadjuvant chemotherapy.

AKR1B10 catalyzes the reduction of highly electrophilic compounds, including cytotoxic α β-unsaturated carbonyls as by-products of cell metabolism and lipid peroxidation ([@b34-ol-0-0-9705]). Unsaturated carbonyls may induce protein dysfunction, DNA damage and apoptosis ([@b35-ol-0-0-9705]). AKR1B10 is able to protect host cells from carbonyl lesions by detoxifying cellular carbonyls and their glutathione conjugates through the conversion of reactive carbonyl groups into less active hydroxyls ([@b37-ol-0-0-9705]--[@b39-ol-0-0-9705]). A study carried out by Luo *et al* ([@b40-ol-0-0-9705]) demonstrated that AKR1B10 protein is secreted by a lysosome-mediated non-classical pathway and is considered to be a tumor marker. It is hypothesized that AKR1B10 promotes cancer cell growth via a number of mechanisms. A study by Matsunaga *et al* ([@b41-ol-0-0-9705]) suggested functions for AKR1B10 in cancer cells, including detoxifying carbonyl compounds, promoting fatty acid and lipid synthesis, reducing farnesal and geranylgeraniol to their alcohols, and reducing retinoic acid. The present study validated the expression of AKR1B10 in AGS and BGC-823 gastric carcinoma cell lines. It was identified that AKR1B10 is localized to the cytoplasm, and is highly expressed in both cell lines. However, much may be learned about the functions of AKR1B10 by either knockout or over expression models in gastric carcinoma cell lines in future studies. AKR1B10 inactivation is not a consequence of promoter hypermethylation or chromosome rearrangement in colon cancer, rather, it results from specific regulation by carcinogenic transcription factors. Several studies have identified multiple putative oncogenic and tumor-suppressor protein-binding sites within the AKR1B10 promoter region, including the transcription factors nuclear factor erythroid 2 like 2, activator protein 1, tumor protein p53, and nuclear factor κ-light-chain-enhancer of activated B cells, and antioxidant response elements ([@b42-ol-0-0-9705],[@b43-ol-0-0-9705]). Despite advances in research, the current understanding of the underlying enzymatic mechanisms, pharmacological modulation, gene regulation and physiological roles of AKR1B10 remain uncertain, thus additional studies are required to resolve the function of AKR1B10 in cellular growth and survival in gastric cancer.

To conclude, AKR1B10 is expressed in the cytoplasm of tumor cells in gastric cancer. Positive expression of AKR1B10 protein is associated with lymph node metastasis and a decreased tumor response to neoadjuvant chemotherapy. AKR1B10-positivity also predicts poorer overall survival in gastric cancer, and may be a useful therapeutic marker for determining appropriate treatment management.
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![Expression of AKR1B10 in gastric carcinoma cell lines by western blotting. Representative bands were aligned with markers Lamin B1 and α-tubulin. The AKR1B10 protein was identified predominantly in cytoplasm. AKR1B10, aldo-ketoreductase family 1 member B10; N, nucleus; c, cytoplasm; M~r~, relative molecular mass; n.s, non-specific band.](ol-17-01-0773-g00){#f1-ol-0-0-9705}

![Representative images of immunohistochemical staining of AKR1B10 in gastric cancer samples. (A) Positive staining of AKR1B10 in (a) well-differentiated (b) moderately-differentiated and (c) poorly-differentiated gastric cancer tissue samples. (B) Negative staining of AKR1B10 in gastric cancer tissue samples (Magnification ×600). AKR1B10, aldo-ketoreductase family 1 member B10.](ol-17-01-0773-g01){#f2-ol-0-0-9705}

![Kaplan-Meier survival curves of patients with gastric cancer who received neoadjuvant chemotherapy according to their AKR1B10 status. The correlation between AKR1B10 expression and overall survival rate was statistically significant (P=0.0372). AKR1B10, aldo-ketoreductase family 1 member B10.](ol-17-01-0773-g02){#f3-ol-0-0-9705}

###### 

Summary of patient\'s general information and management involved in this study. Total number of patients: 53.

  Clinical parameters            Number of cases (n)   (%)
  ------------------------------ --------------------- ------
  Age, years                                           
    \<58                         26                    49.0
    ≥58                          27                    51.0
  Sex                                                  
    Male                         40                    75.5
    Female                       13                    24.5
  Tumor size, cm                                       
    \<5                          34                    64.2
    ≥5                           19                    35.8
  Tumor location                                       
    Cardia, fundus, body         28                    52.8
    Antral                       25                    47.2
  TNM stage                                            
    I--II                        26                    49.0
    III--IV                      27                    51.0
  Tumor depth                                          
    T1-T2                        11                    20.8
    T3-T4                        42                    79.2
  Lymph node metastasis                                
    Yes                          36                    68.0
    No                           17                    32.0
  Histological differentiation                         
    Differentiated               24                    45.3
    Undifferentiated             29                    54.7
  Chemotherapy regimen                                 
    FOLFOX                       22                    41.5
    EOX                          16                    30.2
    Others (SOX, ECX, EOX, S1)   13                    24.5
    Chemoradiotherapy            2                     3.8
  Chemotherapy cycle                                   
    2                            8                     15.1
    3                            17                    32.1
    ≥4                           28                    52.8
  Tumor regression grade                               
    0--2                         33                    62.3
    3--4                         20                    37.7
  Surgical types                                       
    Complete resection           25                    47.2
    Distal resection             25                    47.2
    Proximal resection           1                     1.9
    Partial resection            2                     3.7

ECX, epirubicin + cisplatin + capecitabine; EOS, epirubicin + oxaplatin + tegafur; EOX, epirubicin + oxaplatin + capecitabine; FOLFOX, oxaplatin + leucovorin + 5-FU; S1, tegafur; SOX, oxaplatin + tegafur.

###### 

Correlation of Aldo-ketoreductase family 1 member B10 expression with clinic opathological parameters in gastric cancer patient with neoadjuvant chemotherapy.

                                 AKR1B10 expression               
  ------------------------------ -------------------- ----------- ----------------------------------------------------
  Age, years                                                      0.565
    \<58                         15 (57.7)            11 (42.3)   
    ≥58                          16 (59.3)            11 (40.7)   
  Sex                                                             0.108
    Male                         21 (52.5)            19 (47.5)   
    Female                       10 (76.9)            3 (23.1)    
  Tumor size, cm                                                  0.211
    \<5                          18 (52.9)            16 (47.1)   
    ≥5                           13 (68.4)            6 (31.6)    
  Tumor location                                                  0.236
    Cardia, fundus, body         14 (51.9)            13 (48.1)   
    Antral                       17 (65.4)            9 (34.6)    
  Tumor staging                                                   0.171
    I--II                        13 (50.0)            13 (50.0)   
    III--IV                      18 (66.7)            9 (33.3)    
  Tumor depth                                                     0.259
    T1-T2                        5 (45.5)             6 (54.5)    
    T3-T4                        26 (61.9)            16 (38.1)   
  Lymph node metastasis                                           0.020^[a](#tfn2-ol-0-0-9705){ref-type="table-fn"}^
    Yes                          25 (69.4)            11 (30.6)   
    No                           6 (35.3)             11 (64.7)   
  Histological differentiation                                    0.399
    Differentiated               15 (62.5)            9 (37.5)    
    Undifferentiated             16 (55.2)            13 (44.8)   
  Tumor regression grade                                          0.033^[a](#tfn2-ol-0-0-9705){ref-type="table-fn"}^
    0--2                         23 (69.7)            10 (30.3)   
    3--4                         8 (40.0)             12 (60.0)   
  Chemotherapy regimen                                            0.583
    FOLFOX                       13 (59.1)            9 (40.9)    
    EOX                          8 (50.0)             8 (50.0)    
    Others (SOX, ECX, EOS, S1)   8 (61.5)             5 (38.5)    
    Chemoradiotherapy            2 (100.0)            0 (0.0)     
  Chemotherapy cycle                                              0.768
    2                            4 (50.0)             4 (50.0)    
    3                            11 (64.7)            6 (35.3)    
    ≥4                           16 (57.1)            12 (42.9)   

P-value \<0.05. ECX, epirubicin + cisplatin + capecitabine; EOS, epirubicin + oxaplatin + tegafur; EOX, epirubicin + oxaplatin + capecitabine; FOLFOX, oxaplatin + leucovorin + 5-FU; S1, tegafur; SOX, oxaplatin + tegafur.

###### 

Univariate and multivariate survival analyses of various clinicopathological parameters in gastric cancer patient with neoadjuvant chemotherapy.

                                 Univariate   Multivariate                                     
  ------------------------------ ------------ -------------- ---------------- -------- ------- ---------------
  Age                            0.9304       1.040          0.3953--2.759    0.0643   7.958   0.962--3.985
  Sex                            0.4931       1.481          0.4819--4.549    0.2361   7.595   0.737--3.452
  Tumor size                     0.9655       0.9783         0.3619--2.644    0.1360   0.205   0.025--1.648
  Tumor location                 0.0237       0.3081         0.1111--0.8545   0.6691   1.347   0.343--5.298
  Tumor staging                  0.0066       0.2626         0.1000--0.6897   0.9064   1.806   0.385--2.936
  Tumor depth                    0.2384       0.4545         0.1225--1.686    0.0992   0.476   0.197--1.150
  Lymph node metastasis          0.0006       5.562          2.087--14.82     0.0021   4.750   1.744--12.934
  Histological differentiation   0.5747       0.7574         0.2869--1.999    0.0504   0.465   0.216--1.000
  Tumor regression grade         0.0496       2.635          1.002--6.931     0.0365   0.515   0.277--0.957
  AKR1B10                        0.0372       2.797          1.063--7.359     0.0344   5.230   1.133--24.131

CI, confidence interval; HR, hazards ratio; AKR1B10, Aldo-ketoreductase family 1 member B10.

[^1]: Contributed equally
